全文获取类型
收费全文 | 5540篇 |
免费 | 325篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 368篇 |
妇产科学 | 80篇 |
基础医学 | 757篇 |
口腔科学 | 124篇 |
临床医学 | 446篇 |
内科学 | 1068篇 |
皮肤病学 | 115篇 |
神经病学 | 307篇 |
特种医学 | 117篇 |
外科学 | 793篇 |
综合类 | 193篇 |
一般理论 | 3篇 |
预防医学 | 331篇 |
眼科学 | 133篇 |
药学 | 562篇 |
1篇 | |
中国医学 | 41篇 |
肿瘤学 | 403篇 |
出版年
2023年 | 33篇 |
2022年 | 79篇 |
2021年 | 185篇 |
2020年 | 98篇 |
2019年 | 130篇 |
2018年 | 155篇 |
2017年 | 114篇 |
2016年 | 133篇 |
2015年 | 162篇 |
2014年 | 211篇 |
2013年 | 275篇 |
2012年 | 349篇 |
2011年 | 333篇 |
2010年 | 218篇 |
2009年 | 179篇 |
2008年 | 285篇 |
2007年 | 244篇 |
2006年 | 274篇 |
2005年 | 241篇 |
2004年 | 195篇 |
2003年 | 184篇 |
2002年 | 179篇 |
2001年 | 134篇 |
2000年 | 145篇 |
1999年 | 122篇 |
1998年 | 67篇 |
1997年 | 43篇 |
1996年 | 30篇 |
1995年 | 28篇 |
1994年 | 26篇 |
1993年 | 23篇 |
1992年 | 92篇 |
1991年 | 78篇 |
1990年 | 70篇 |
1989年 | 75篇 |
1988年 | 71篇 |
1987年 | 58篇 |
1986年 | 62篇 |
1985年 | 56篇 |
1984年 | 42篇 |
1983年 | 24篇 |
1982年 | 23篇 |
1979年 | 39篇 |
1977年 | 31篇 |
1975年 | 33篇 |
1974年 | 29篇 |
1973年 | 25篇 |
1972年 | 32篇 |
1971年 | 25篇 |
1968年 | 21篇 |
排序方式: 共有5911条查询结果,搜索用时 22 毫秒
101.
102.
103.
104.
The tipping point: The critical role of therapeutic apheresis in a case of refractory acquired hemophilia
下载免费PDF全文
![点击此处可从《Journal of clinical apheresis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Michael Losos Scott Scrape Sarita Joshi Aaron Shmookler Jian Chen 《Journal of clinical apheresis》2017,32(6):564-566
Acquired hemophilia A (AHA) is a rare autoimmune disorder that leads to factor VIII (FVIII) deficiency via autoantibody formation. Standard treatment options include FVIII bypassing factors and immunosuppression. However, the role of therapeutic plasma exchange (TPE) is not clear in the treatment of AHA. We present a case of idiopathic AHA in a 66 year old female with severe bleeding and a FVIII inhibitor of 17.6 Bethesda units (BU). She failed to respond to standard treatment including maximum dose of recombinant FVIIa (rFVIIa), rituximab, and other immunosuppressive agents. Her FVIII inhibitor rapidly increased to 140 BU and FVIII was below 5%. TPE was initiated 3 weeks after admission and her bleeding stabilized after the first treatment and completely stopped after three treatments. Repeat testing revealed increased FVIII to 15% and FVIII inhibitor decreased to 2.0 BU. After an additional TPE treatment, her FVIII increased to 27% and FVIII inhibitor decreased to 0.6 BU and she was discharged without bleeding 40 days after admission. In this case, TPE played a critical role in reducing FVIII inhibitor, which resulted in a recovery of FVIII activity and hemostasis. Therefore, TPE should be initiated early in AHA patients with bleeding and high titer of FVIII inhibitor. 相似文献
105.
106.
Hui Yu Zhengming Chen Karla V. Ballman Mark A. Watson Ramaswamy Govindan Irena Lanc David G. Beer Raphael Bueno Lucian R. Chirieac Michael Herman Chui Guoan Chen Wilbur A. Franklin David R. Gandara Carlo Genova Kristine A. Brovsky Mary-Beth M. Joshi Daniel T. Merrick William G. Richards Fred R. Hirsch 《Journal of thoracic oncology》2019,14(1):25-36
Objectives
Anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in stage IB to IIIA NSCLC. In addition, several clinical trials using anti–PD-1/PD-L1 immunotherapy as an adjuvant or neoadjuvant treatment in patients with resectable stage NSCLC are ongoing. However, few analyses of anti–PD-1/PD-L1 immunotherapy–related biomarkers in early-stage squamous cell lung carcinoma (SqCLC) have been reported. In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC, providing data for identifying the potential role for patients with anti–PD-1/PD-L1 treatment in early-stage SqCLC.Methods
A total of 255 specimens from patients with early-stage SqCLC were identified within participating centers of the Strategic Partnering to Evaluate Cancer Signatures program. PD-L1 protein expression by immunohistochemistry was evaluated by using the Dako PD-L1 22C3 pharmDx kit on the Dako Link 48 auto-stainer (Dako, Carpinteria, CA). Tumor mutation burden (TMB) was calculated on the basis of data from targeted genome sequencing. The T-effector and interferon gamma (IFN-γ) gene signature was determined from Affymetrix gene chip data (Affymetrix, Santa Clara, CA) from frozen specimens.Results
The prevalence of PD-L1 expression was 9.8% at a tumor proportion score cutoff of at least 50%. PD-L1 mRNA and programmed cell death 1 ligand 2 mRNA positively correlated with PD-L1 protein expression on tumor cells (TCs) and tumor-infiltrating immune cells. PD-L1 protein expression on tumor-infiltrating immune cells was correlated with the T-effector and IFN-γ gene signature (p < 0.001), but not with TMB. For TCs, all of these biomarkers were independent of each other and neither PD-L1 protein expression, TMB, or T-effector and IFN-γ gene signatures were independently prognostic for patient outcomes.Conclusions
Evaluation of PD-L1 expression, TMB, and T-effector and IFN-γ gene signatures in the cohort with early-stage SqCLC found them to be independent of each other, and none was associated with overall survival. Our results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells. 相似文献107.
108.
109.
110.
Smita Joshi Richard Muwonge Vinay Kulkarni Mahesh Mandolkar Eric Lucas Sanjay Pujari Rengaswamy Sankaranarayanan Partha Basu 《International journal of cancer. Journal international du cancer》2023,152(2):249-258
We are reporting (a) updated incidence of cervical intraepithelial neoplasia (CIN) among women who did not have colposcopic or histopathological disease at baseline and (b) disease outcomes among women treated for CIN and their follow-up HPV status; in a cohort of women living with HIV (WHIV). The median overall follow-up was 3.5 years (IQR 2.8-4.3). The incidence of any CIN and that of CIN 2 or worse disease was 16.7 and 7.0 per 1000 person-years of observation (PYO), respectively. Compared with women who were HPV negative at baseline, women who cleared HPV infection had 23.95 times increased risk of incident CIN 2 or worse lesions (95% CI 2.40-661.07). Women with persistent HPV infection had 138.18 times increased risk of CIN 2 or worse lesions (95% CI 20.30-3300.22). Complete disease regression was observed in 65.6% of the HPV positive women with high-grade CIN and were treated with thermal ablation but HPV persistence was seen in 44.8% of those with high-grade disease. Among those who did not have any disease at baseline and were also HPV negative, about 87% (95% CI 83.79-89.48) women remained HPV negative during consecutive HPV test/s with the median interval of 3.5 years. Long-term surveillance of WHIV treated for any CIN is necessary for the prevention of cervical cancer among them. Our study provides an early indication that the currently recommended screening interval of 3 to 5 years among WHIV may be extended to at least 5 years among HPV negative women. Increasing the screening interval can be cost saving and improve scalability among WHIV to support WHO's cervical cancer elimination initiative. 相似文献